New ELISA for quantitation of human urokinase receptor (CD87) in cancer.

Keyphrases

• Enzyme-linked Immunosorbent Assay (ELISA) 100%
• Soluble Urokinase Plasminogen Activator Receptor (suPAR) 100%
• In Cancer 100%
• CD87 100%
• Assay Formats 35%
• Breast Cancer Patients 15%
• Recombinant 15%
• Soluble uPAR 15%
• Chicken Antibody 15%
• Plasminogen Activator inhibitor-1 (PAI-1) 10%
• Prognostic Relevance 10%
• Monoclonal Antibody 10%
• Lysate 10%
• Urokinase-type Plasminogen Activator 10%
• Breast Cancer Cell Lines 10%
• Antigen Content 10%
• Tissue Extracts 10%
• Commercially Available 5%
• Tumor 5%
• Coefficient of Variation 5%
• Sandwich Structure 5%
• Tumor Tissue 5%
• Non-associated 5%
• Low Detection Limit 5%
• Recurrent Disease 5%
• Epitope 5%
• Recovery Rate 5%
• Cell Lysate 5%
• Overall Survival 5%
• Monocytes 5%
• Primary Breast Cancer 5%
• Disease-free Survival 5%
• Patient Prognosis 5%
• Serine Protease 5%
• Nonmalignant 5%
• Cancer Metastasis 5%
• Cancer Invasion 5%
• Non-tumor Cells 5%
• Linear Dose Response 5%
• Epitheloid 5%
• Malignant Epithelial Cells 5%
• Fibroblastic 5%
• Tumor Cell Lysate 5%
• Assay Variation 5%
• Breast Cancer Tissues 5%
• Antigen Levels 5%
• Non-malignant Cells 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Enzyme-Linked Immunosorbent Assay 100%
• Malignant Neoplasm 100%
• Urokinase Receptor 100%
• Breast Cancer 30%
• Neoplasm 20%
• Tissue Extract 10%
• Monoclonal Antibody 10%
• Urokinase 10%
• Overall Survival 5%
• Receptor 5%
• Recurrent Disease 5%
• Disease Free Survival 5%
• Serine Proteinase 5%
• Epitope 5%

Immunology and Microbiology

• Urokinase Receptor 100%
• Enzyme-Linked Immunosorbent Assay 100%
• Cell Lysate 20%
• Tumor Cell 10%
• Breast Cancer Cell Line 10%
• Monoclonal Antibody 10%
• Tissue Extract 10%
• Epitope 5%
• Overall Survival 5%
• Cancer Cell 5%
• Conformation 5%
• Dose Response 5%
• Cell Invasion 5%
• Disease Free Survival 5%
• Cancer Tissue 5%
• Serine 5%